# Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Source: https://onco.cc/trials/nct05732831/  
OnCo record `nct05732831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TNG462 and Pembrolizumab in advanced solid tumours, run by Tango Therapeutics, Inc., now recruiting.

## Summary

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors is a phase 1/2 interventional study registered as NCT05732831 by Tango Therapeutics, Inc., with 225 participants planned, started 2023-05-26 and due to reach its primary completion in 2027-06. Interventions recorded: TNG462 and Pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05732831
- Phase: 1/2
- Setting: A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
- Sponsor: Tango Therapeutics, Inc.
- Enrolled: 225

## Sources

- ClinicalTrials.gov NCT05732831: https://clinicaltrials.gov/study/NCT05732831

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [TNG462](https://onco.cc/drugs/tng462/)
- companies: [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05732831.json